Viking Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 7, 2024
VKTX$28.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Cash flows from operating activities | |||
| Net loss | $(85,895) | $(68,867) | $(54,990) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| (Accretion) amortization of investment premiums | (8,202) | 1,217 | 3,906 |
| Amortization of financing costs | 88 | 59 | 18 |
| Stock-based compensation | 16,750 | 8,673 | 6,100 |
| Amortization of right-of-use assets | 292 | 291 | 296 |
| Interest expense related to operating lease liability | 43 | 41 | 11 |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | 6,408 | (3,130) | (711) |
| Accrued interest, net of interest receivable on maturity of investments | 321 | 614 | 1,176 |
| Accounts payable | (1,018) | 7,085 | (2,544) |
| Accrued expenses | (1,816) | 5,809 | (506) |
| Lease liability | (347) | (189) | (342) |
| Net cash used in operating activities | (73,376) | (48,397) | (47,586) |
| Cash flows from investing activities | |||
| Purchases of investments | (478,303) | (121,431) | (168,015) |
| Proceeds from sales and maturities of investments | 299,217 | 176,184 | 205,975 |
| Net cash (used in) provided by investing activities | (179,086) | 54,753 | 37,960 |
| Cash flows from financing activities | |||
| Public offering, net of offering costs | 269,760 | (22) | (46) |
| Value of shares withheld related to employee tax withholding | (7,121) | (1,533) | (707) |
| Repurchase of common stock | — | (6,795) | — |
| Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan | 6,768 | 848 | 7,633 |
| ATM offering, net of fees | 1,969 | 11,665 | — |
| Net cash provided by financing activities | 271,376 | 4,163 | 6,880 |
| Net increase (decrease) in cash and cash equivalents | 18,914 | 10,519 | (2,746) |
| Cash and cash equivalents beginning of period | 36,632 | 26,371 | 29,117 |
| Effect of exchange rate changes on cash | (30) | (258) | - |
| Cash and cash equivalents end of period | $55,516 | $36,632 | $26,371 |
| Supplemental disclosure of non-cash investing and financing transactions | |||
| Unpaid deferred public offering and other financing costs | $50 | $31 | $50 |
| Right-of-use asset obtained in exchange for lease obligation | $— | $1,664 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.